VEGF Trap induces antiglioma effect at different stages of disease

Neuro-Oncology

Volumn 10, Issue 6, 2008, Pages 940-945

  Gomez Manzano, Candelaria ^a   Holash, Jocelyn ^b   Fueyo, Juan ^a   Xu, Jing ^a   Conrad, Charles A ^a   Aldape, Kenneth D ^a   De Groot, John F ^a   Ekele, B Nebiyou ^a   Yung, W K Alfred ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b REGENERON PHARMACEUTICALS INC   (United States)

Author keywords

Glioblastoma; Therapy; VEGF; VEGF Trap

Indexed keywords

AFLIBERCEPT; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; HYBRID PROTEIN;

ADVANCED CANCER; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INVASION; CANCER MODEL; CANCER STAGING; CANCER SURVIVAL; CELL STRAIN U 87 MG; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; EXPERIMENTAL MODEL; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN CELL; LONG TERM CARE; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; OVERALL SURVIVAL; PHENOTYPE; SPRAGUE DAWLEY RAT; TREATMENT DURATION; TUMOR GROWTH; ANIMAL; BRAIN TUMOR; DRUG ADMINISTRATION; DRUG SCREENING; MOUSE; NUDE MOUSE; PATHOLOGY;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; GLIOMA; HUMANS; MICE; MICE, NUDE; RECOMBINANT FUSION PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 60549106878     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1215/15228517-2008-061     Document Type: Article

References (21)

1. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007;11:83-95.
2. Pope WB, Lai A, Nghiemphu P, et al. MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology. 2006;66:1258-1260.
3. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res. 2007;13:1253-1259.
4. Jain RK, di Tomaso E, Duda DG, et al. Angiogenesis in brain tumours. Nat Rev Neurosci. 2007;8:610-622.
5. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA. 2002;99:11393-11398.
6. Byrne AT, Ross L, Holash J, et al. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res. 2003;9:5721-5728.
7. Kim ES, Serur A, Huang J, et al. Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc Natl Acad Sci USA. 2002;99:11399-11404.
8. Riely GJ, Miller VA. Vascular endothelial growth factor trap in non small cell lung cancer. Clin Cancer Res. 2007;13:s4623-s4627.
9. Verheul HM, Hammers H, van Erp K, et al. Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model. Clin Cancer Res. 2007;13:4201-4208.
10. Wachsberger PR, Burd R, Cardi C, et al. VEGF trap in combination with radiotherapy improves tumor control in u87 glioblastoma. Int J Radiat Oncol Biol Phys. 2007;67:1526-1537.
11. Blouw B, Song H, Tihan T, et al. The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell. 2003;4:133-146.
12. Roberts WG, Delaat J, Nagane M, et al. Host microvasculature influence on tumor vascular morphology and endothelial gene expression. Am J Pathol. 1998;153:1239-1248.
13. Lee OH, Fueyo J, Xu J, et al. Sustained angiopoietin-2 expression disrupts vessel formation and inhibits glioma growth. Neoplasia. 2006;8:419-428.
14. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer. 2003;3:401-410.
15. Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science. 1999;284:1994-1998.
16. Rudge JS, Holash J, Hylton D, Russell M, et al. Inaugural article: VEGF Trap complex formation measures production rates of VEGF, providing a biomarker for predicting efficacious angiogenic blockade. Proc Natl Acad Sci USA. 2007;104:18363-18370.
17. Kunkel P, Ulbricht U, Bohlen P, et al. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res. 2001;61:6624-6628.
18. Rubenstein JL, Kim J, Ozawa T, et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia. 2000;2:306-314.
19. Kerbel RS, Yu J, Tran J, et al. Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches. Cancer Metastasis Rev. 2001;20:79-86.
20. Miller KD, Sweeney CJ, Sledge GW Jr. The snark is a boojum: the continuing problem of drug resistance in the antiangiogenic era. Ann Oncol. 2003;14:20-28.
21. Kleihues P, Burger PC, Scheithauer BW. Histological typing of tumours of the central nervous system. 2nd ed. Berlin: Springer; 1993:1-105.